Alventa XL 75mg capsules

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Venlafaxine hydrochloride

Available from:

Krka UK Ltd

ATC code:

N06AX16

INN (International Name):

Venlafaxine hydrochloride

Dosage:

75mg

Pharmaceutical form:

Modified-release capsule

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04030400; GTIN: 5391512450656

Patient Information leaflet

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if their symptoms are the same
as yours.
•
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet, please tell your doctor or
pharmacist.
IN THIS LEAFLET:
1. What Alventa XL is and what it is used for
2. Before you take Alventa XL
3. How to take Alventa XL
4. Possible side effects
5. How to store Alventa XL
6. Further information
1. WHAT ALVENTA XL IS AND WHAT IT IS USED FOR
Alventa XL is an antidepressant that belongs to a group of medicines
called serotonin and norepinephrine reuptake inhibitors
(SNRIs). This group of medicines is used to treat depression and other
conditions such as anxiety disorders. It is thought that
people who are depressed and/or anxious have lower levels of serotonin
and noradrenaline in the brain. It is not fully understood
how antidepressants work, but they may help by increasing the levels
of serotonin and noradrenaline in the brain.
Alventa XL is a treatment for adults with depression. Alventa XL is
also a treatment for adults with the following anxiety
disorder: social anxiety disorder (fear or avoidance of social
situations). Treating depression or anxiety disorders properly is
important to help you get better. If it is not treated, your condition
may not go away and may become more serious and more
difficult to treat.
2. BEFORE YOU TAKE ALVENTA XL
DO NOT TAKE ALVENTA XL
•
If you are allergic to venlafaxine or any of the other ingredients of
Alventa XL.
•
If you are also taking or have taken any time within the last 14 days
any medicines known as irreversible monoamine oxidase
inhibitors (MAOIs), used to treat depression or Parkinson’s disease.
Taking an irreversible MAOI together with other medicines,
including Alventa XL, can cause se

Summary of Product characteristics

OBJECT 1
ALVENTA XL 75 MG PROLONGED-RELEASE CAPSULES,
HARD
Summary of Product Characteristics Updated 20-May-2016 | Consilient
Health Ltd
1. Name of the medicinal product
Alventa XL 75 mg prolonged release capsules, hard
2. Qualitative and quantitative composition
Alventa XL 75 mg: Each prolonged release capsule, hard, contains 75 mg
venlafaxine (as 84.85 mg
venlafaxine hydrochloride).
Excipient with known effect:
75 mg capsule
sucrose
65 mg
For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Prolonged release capsule, hard.
Alventa XL 75 mg_: _opaque, light pink, prolonged release, hard
gelatine capsules containing of white to
off-white pellets.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of major depressive episodes.
For prevention of recurrence of major depressive episodes.
Treatment of Social Anxiety Disorder (SAD).
4.2 Posology and method of administration
Posology
Major depressive episodes
The recommended starting dose for prolonged-release venlafaxine is 75
mg given once daily. Patients not
responding to the initial 75 mg/day dose may benefit from dose
increases up to a maximum dose of 375
mg/day. Dosage increases can be made at intervals of 2 weeks or more.
If clinically warranted due to
symptom severity, dose increases can be made at more frequent
intervals, but not less than 4 days.
Because of the risk of dose-related adverse effects, dose increments
should be made only after a clinical
evaluation (see section 4.4). The lowest effective dose should be
maintained.
Patients should be treated for a sufficient period of time, usually
several months or longer. Treatment
should be reassessed regularly on a case-by-case basis. Longer-term
treatment may also be appropriate for
prevention of recurrence of major depressive episodes (MDE). In most
of the cases, the recommended
dose in prevention of recurrence of MDE is the same as the one used
during the current episode.
Antidepressive medicinal products should continue for at least six
months following remission.
Social anxiet